NGM Biopharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    5493008V5DSDZIGQOP17
    ISIN
    US62921N1054 (NGM)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €3.79M
    Gross margin
    26.3%
    EBIT
    -€129.96M
    EBIT margin
    -3,429.1%
    Net income
    -€119.97M
    Net margin
    -3,165.7%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Add to watchlist

    Notifications